Britain and America have established a landmark bilateral deal that will guarantee no tariffs on British drug products entering the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to increase funding on medicines through the NHS. This move guarantees that duties on these vital exports will be held at nothing for a timeframe of 36 months.
This deal comes after previous statements to hike import taxes on branded pharmaceutical imports, with figures floated as high as double the cost.
"This arrangement between the United Kingdom bolsters the global environment for new treatments and introduces long-overdue balance to American-British medicine commerce," a release said.
Commercial Importance
Drugs represent one of the Britain's largest exports to the America, which is easily the primary destination for leading UK drugmakers.
Export figures show that in the 12 months prior to September, the UK sold drugs worth £11.1bn to the US. This amount represented 17.4% of total UK exports in that timeframe.
"This guarantee safeguards jobs, boosts capital expenditure and facilitates the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Specific British Pledges
The pact entails several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to increase total NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Payback Limit: The percentage manufacturers must return to the NHS to control costs will be capped at fifteen percent. Previously, rebates exceeded 20%.
Recent Tensions
The deal comes amid a long-running row between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
The disagreement were exacerbated by arguments that American patients were charged significantly more for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been pledged toward American operations.
A senior figure publicly accepted that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the last ten years.
